Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Obicetrapib in Moderate Hepatic Impairment
NCT06048302Phase 1Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of obicetrapib in hypercholesterolemia and dyslipidemia (2 arms), sponsored by NewAmsterdam Pharma. Primary endpoints: Area under the curve from dosing time to infinity, Area under curve from dosing time to last measurement and 1 more. Started Nov 2023; status: completed.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on NCT06048302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048302.